白血病·淋巴瘤
白血病·淋巴瘤
백혈병·림파류
JOURNAL OF LEUKEMIA & LYMPHOMA
2013年
12期
739-741
,共3页
郭慧敏%朱镭%王宏伟%黄瑞%张晋丽
郭慧敏%硃鐳%王宏偉%黃瑞%張晉麗
곽혜민%주뢰%왕굉위%황서%장진려
白血病%Fms样酪氨酸激酶3%串联重复序列%聚合酶链反应
白血病%Fms樣酪氨痠激酶3%串聯重複序列%聚閤酶鏈反應
백혈병%Fms양락안산격매3%천련중복서렬%취합매련반응
Leukemia%FMS-like tyrosine kinase 3%Tandem repeat sequences%Polymerase chain reaction
目的 分析急性髓系白血病(AML)患者骨髓FMS样酪氨酸激酶3基因内部串联重复(FLT3/ITD)突变情况.方法 采用聚合酶链反应方法检测96例初发AML患者FLT3/ITD突变,分析FLT3/ITD阳性患者的临床特征.结果 96例AML患者中FLT3/ITD突变18例(18.8%).其中M22例,M3 11例,M42例,M53例.FLT3/ITD阳性AML患者初发时外周血白细胞计数中位数为18.0×109/L(3.6× 109~ 137.6×109/L),FLT3/ITD阴性AML患者为6.3×109/L(4.5×109 ~ 113.0×109/L),两组比较差异有统计学意义(t=3.04,P<0.05).FLT3/ITD阳性者随访16例,中位随访时间10个月(6~ 15个月),13例处于第1次完全缓解.诱导缓解率为81.3%(13/16).结论 FLT3/ITD是AML患者常见的基因突变,FLT3/ITD阳性患者白细胞计数较高.
目的 分析急性髓繫白血病(AML)患者骨髓FMS樣酪氨痠激酶3基因內部串聯重複(FLT3/ITD)突變情況.方法 採用聚閤酶鏈反應方法檢測96例初髮AML患者FLT3/ITD突變,分析FLT3/ITD暘性患者的臨床特徵.結果 96例AML患者中FLT3/ITD突變18例(18.8%).其中M22例,M3 11例,M42例,M53例.FLT3/ITD暘性AML患者初髮時外週血白細胞計數中位數為18.0×109/L(3.6× 109~ 137.6×109/L),FLT3/ITD陰性AML患者為6.3×109/L(4.5×109 ~ 113.0×109/L),兩組比較差異有統計學意義(t=3.04,P<0.05).FLT3/ITD暘性者隨訪16例,中位隨訪時間10箇月(6~ 15箇月),13例處于第1次完全緩解.誘導緩解率為81.3%(13/16).結論 FLT3/ITD是AML患者常見的基因突變,FLT3/ITD暘性患者白細胞計數較高.
목적 분석급성수계백혈병(AML)환자골수FMS양락안산격매3기인내부천련중복(FLT3/ITD)돌변정황.방법 채용취합매련반응방법검측96례초발AML환자FLT3/ITD돌변,분석FLT3/ITD양성환자적림상특정.결과 96례AML환자중FLT3/ITD돌변18례(18.8%).기중M22례,M3 11례,M42례,M53례.FLT3/ITD양성AML환자초발시외주혈백세포계수중위수위18.0×109/L(3.6× 109~ 137.6×109/L),FLT3/ITD음성AML환자위6.3×109/L(4.5×109 ~ 113.0×109/L),량조비교차이유통계학의의(t=3.04,P<0.05).FLT3/ITD양성자수방16례,중위수방시간10개월(6~ 15개월),13례처우제1차완전완해.유도완해솔위81.3%(13/16).결론 FLT3/ITD시AML환자상견적기인돌변,FLT3/ITD양성환자백세포계수교고.
Objective To analyze the mutations of FMS-like tyrosine kinase 3 internal tandem duplication (FLT3/ITD) in bone marrow cells of patients with newly-diagnosed acute myeloid leukemia (AML).Methods The mutations of FLT3/ITD in 96 AML cases were detected by polymerase chain reaction (PCR)and the clinical features of FLT3/ITD positive patients were analyzed.Results FLT3/ITD mutations were identified in 18 patients (18.8 %),2 cases were M2,11 cases were M3,2 cases were M4,3 cases were Ms.Patients with FLT3/ITD mutations presented higher initial white blood cell count than that of patients without FLT3/ITD mutations [18.0×109/L (3.6×109-137.6×109/L) vs 6.3×109/L (4.5×109-113.0×109/L),t =3.04,P < 0.05].Out of FLT3/ITD positive patients,13/16 (81.3 %) obtained complete remission and 13 patients remained in first remission in a median follow-up of 10 months(6-15 months).Conclusion The mutations of FLT3/ITD are frequently identified in newly-diagnosed AML patients,patients with FLT3/ITD mutations present high white blood cell count.